Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Entera Bio Ltd., a clinical stage biotechnology company specializing in oral peptide and protein therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The company highlighted its lead oral osteoanabolic candidate EB613 for osteoporosis and other pipeline programs, …